This website is intended for UK Healthcare Professionals. Adverse event reporting can be found at the bottom of this page.
CYTISINICLINE is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. The treatment goal of CYTISINICLINE is the permanent cessation of the nicotine-containing products use.
CYTISINICLINE (previously used name: Cytisine). Access the full Summary of Product Characteristics via Consilient Health website or eMC
From 1st November 2025, Cytisine 1.5mg tablets from Consilient Health were renamed Cytisinicline 1.5 mg tablets in line with WHO nomenclature recommendations. The product otherwise remains unchanged. Please note product in “Cytisine” packaging will remain in the supply chain until current stocks are exhausted.
CYTISINE is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. The treatment goal of CYTISINE is the permanent cessation of the nicotine-containing products use.
CYTISINE (also known as cytisinicline). Access the full Summary of Product Characteristics via Consilient Health website or eMC
ASH, an independent public health charity, ran a webinar on varenicline & Cytisinicline (Previously used name: Cytisine) on the 16th of December 2024. You can find a link to the webinar hosted on the ASH website, as well as a short summary below. Click here to watch the webinar -- On 16th December 2024, ASH hosted a Smokefree NHS Network online event on the smoking cessation medications varenicline and Cytisinicline (Previously used name: Cytisine). The webinar provided an overview of varenicline and Cytisinicline, a case study from Greater Manchester on their use in trusts and a summary of the NCSCT training materials and briefings on these medications. There were also presentations from the Specialist Pharmacy Service on Patient Group Directions and Fresh who are working with local authorities and pharmacy colleagues to develop a regional PGD Pharmacy supply service for varenicline & Cytisinicline, in the community. -- We would like to thank ASH for giving permission to share this link. Please note that ASH is an independent organisation and the inclusion of this link does not imply any endorsement or affiliation between Consilient Health and ASH.
NICE guideline NG209 has been updated to include Cytisinicline (Previously used name: Cytisine).¹ Cytisinicline has been classified as among the "more likely" interventions to result in successful quitting for UK smokers in the updated NICE NG209 guidelines.¹ The NICE Guidelines mandate that healthcare providers ensure Cytisinicline is made available to smokers as a treatment option alongside other current therapies. To read the full updated guidance Click here Cytisinicline, an effective treatment and supported by decades of use in Eastern Europe, is now endorsed by NICE giving healthcare professionals an additional option for smoking cessation1-4 1. NICE NG209. Tobacco: preventing uptake, promoting quitting and treating dependence. https://www.nice.org.uk/guidance/ng209 2. Cytisinicline Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/15789/ 3. Prochaska JJ, Das S, Benowitz NL. Cytisine, the world's oldest smoking cessation aid. BMJ. 2013 Aug 23;347:f5198. doi: 10.1136/bmj.f5198. PMID: 23974638. 4. Karnieg T et al. Cytisine for smoking cessation. CMAJ: 2018 Cited at: https://www.cmaj.ca/content/190/19/e596
Following a directed appraisal by All Wales Medicines Strategy Group, Cytisinicline (Previously used name: Cytisine) is recommended as an option for use within NHS Wales for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. Click here to access
